BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection

Annals of Oncology

Volumn 14, Issue 10, 2003, Pages 1562-1569

  Hartmann, Pia ^a,b   Rehwald, U ^a   Salzberger, B ^b   Franzen, C ^b   Sieber, M ^a   Wohrmann A ^a   Diehl, V ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Antiretroviral therapy; Chemotherapy; HIV infection; Hodgkin's disease

Indexed keywords

ABACAVIR; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CD4 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INDINAVIR; LAMIVUDINE; NELFINAVIR; PREDNISONE; PROCARBAZINE; RITONAVIR; STAVUDINE; VINCRISTINE; VINCRISTINE SULFATE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; RNA; TREATMENT OUTCOME; VINCRISTINE;

EID: 0142154396     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg408     Document Type: Article

References (29)

1. Powles T, Bower M. HIV-associated Hodgkin's disease. Int J STD AIDS 2000; 11: 492-494.
2. Tsimberidou AM, Sarris AH, Medeiros LJ et al. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma 2001; 41: 535-544.
3. Re A, Casari S, Cattaneo C et al. Hodgkin's disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin's lymphoma. Cancer 2001; 92: 2739-2745.
4. Dolcetti R, Boiocchi M, Gloghini A et al. Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 2001; 37: 1276-1287.
5. Tirelli U, Errante D, Dolcetti R et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995; 13: 1758-1767.
6. Andrieu JM, Roithmann S, Tourani JM et al. Hodgkin's disease during HIV 1 infection: the French registry experience. French Registry of HIV-associated Tumors. Ann Oncol 1993; 4: 635-641.
7. Rubio R. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid. Cancer 1994; 73: 2400-2407.
8. Levine AM. Hodgkin's disease in the setting of human immunodeficiency virus infection. J Natl Cancer Inst Monogr 1998; 23: 37-42.
9. Ree HJ, Strauchen JA, Khan AA et al. Human immunodeficiency virus-associated Hodgkin's disease. Clinicopathologic studies of 24 cases and preponderance of mixed cellularity type characterized by the occurrence of fibrohistiocytoid stromal cells. Cancer 1991; 67: 1614-1621.
10. Ames ED, Conjalka MS, Goldberg AF et al. Hodgkin's disease and AIDS. Twenty-three new cases and a review of the literature. Hematol Oncol Clin North Am 1991; 5: 343-356.
11. Tirelli U, Errante D, Vaccher E et al. Hodgkin's disease in 92 patients with HIV infection: the Italian experience. Italian Cooperative Group on AIDS & Tumors (GICAT). Ann Oncol 1992; 3 (Suppl 4): 69-72.
12. Errante D, Tirelli U, Gastaldi R et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT). Cancer 1994; 73: 437-444.
13. Errante D, Gabarre J, Ridolfo AL et al. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol 1999; 10: 189-195.
14. Levine AM. HIV-associated Hodgkin's disease. Biologic and clinical aspects. Hematol Oncol Clin North Am 1996; 10: 1135-1148.
15. Diehl V, Franklin J, Hasenclever D et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810-3821.
16. Diehl V, Franklin J, Paulus U et al. BEACOPP chemotherapy improves survival and dose escalation further improves tumor control in advanced-stage Hodgkin's disease: GHSG HD9 results. Leuk Lymphoma 2001; 42 (Suppl 2): 16 (Abstr I-47).
17. Zubrod CG, Schneiderman M, Frei E 3rd et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphamide. J Chronic Dis 1960; 11: 7-33.
18. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
19. US Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
20. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1999 USPHS/IDSA for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. J Infect Dis 2000; 20: 29-65.
21. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
22. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
23. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
24. Diehl V, Franklin J, Hasenclever D et al. BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998; 9: S67-S71.
25. Levine AM, Li P, Cheung T et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24: 444-450.
26. Spina M, Gabarre J, Rossi G et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection. Blood 2002; 100: 1984-1988.
27. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
28. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483-1491.
29. Matthews GV, Bower M, Mandalia S et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730-2734.